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& Peter Bradding
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited therapeutic 
options. KCa3.1 ion channels play a critical role in TGFβ1-dependent pro-fibrotic responses in human 
lung myofibroblasts. We aimed to develop a human lung parenchymal model of fibrogenesis and test 
the efficacy of the selective KCa3.1 blocker senicapoc. 2 mm3 pieces of human lung parenchyma were 
cultured for 7 days in DMEM ± TGFβ1 (10 ng/ml) and pro-fibrotic pathways examined by RT-PCR, 
immunohistochemistry and collagen secretion. Following 7 days of culture with TGFβ1, 41 IPF- and 
fibrosis-associated genes were significantly upregulated. Immunohistochemical staining demonstrated 
increased expression of ECM proteins and fibroblast-specific protein after TGFβ1-stimulation. Collagen 
secretion was significantly increased following TGFβ1-stimulation. These pro-fibrotic responses 
were attenuated by senicapoc, but not by dexamethasone. This 7 day ex vivo model of human lung 
fibrogenesis recapitulates pro-fibrotic events evident in IPF and is sensitive to KCa3.1 channel inhibition. 
By maintaining the complex cell-cell and cell-matrix interactions of human tissue, and removing cross-
species heterogeneity, this model may better predict drug efficacy in clinical trials and accelerate drug 
development in IPF. KCa3.1 channels are a promising target for the treatment of IPF.
Idiopathic pulmonary fibrosis (IPF) is a common, progressive and invariably fatal lung disease1–3. Median survival 
is 3 years4, and there are currently only two licensed treatments, pirfenidone5 and nintedanib6. The mechanism 
of action of pirfenidone is poorly understood, while nintedanib is an inhibitor of PDGF/VEGF/FGF receptor 
tyrosine kinases6,7. Both drugs are of limited efficacy6,7 and often poorly tolerated. More effective treatments are 
therefore required urgently.
The causes of IPF remain unresolved, but evidence favours alveolar epithelial cell injury as the initial event 
which triggers the release of TGFβ18, a central pro-fibrotic growth factor driving lung parenchymal fibrosis9,10. 
Working in concert with additional growth factors including PDGF11 and FGF212, TGFβ1 drives the formation 
of fibroblast foci and the exaggerated deposition of extracellular matrix (ECM). Repeated injury at different sites 
within the lung generates multifocal areas of pathology at different stages of development13.
Animal models make an important contribution to the study of disease mechanisms and therapeutic strate-
gies. However modelling human disease is extremely difficult, and this appears particularly so for IPF14. Major 
discrepancies between drug effects in the bleomycin mouse model of lung fibrosis and human clinical trials 
for IPF are evident15. Until 2006, 246 experimental studies describing beneficial anti-fibrotic compounds in the 
bleomycin model were reported16, but to-date, only 2 drugs have been licenced. There is therefore a need for addi-
tional models of human lung fibrogenesis which can help predict drug efficacy in IPF.
Ex vivo models of human tissue are already used for pharmacological studies. Precision-cut lung slices and 
airway organ baths are useful for investigating airway biology17,18, while ex vivo culture of human prostate tissue 
has provided clinically relevant insights into prostate carcinogenesis19. A key advantage of using human tissue 
is that it not only removes cross-species heterogeneity in tissue responses to injury and drug intervention, but it 
also retains native tissue architecture and cell-cell signalling pathways that are lost with the study of isolated cells.
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KCa3.1 ion channels are a promising target for IPF. These Ca2+-activated K+ channels regulate constitutive 
and TGFβ1-dependent pro-fibrotic activity in human lung myofibroblasts by promoting Ca2+ influx, SMAD2/3 
phosphorylation and nuclear translocation, α-smooth muscle actin (αSMA) expression/stress fibre formation, 
and cell contraction20–22. KCa3.1 channels promote bleomycin-dependent lung parenchymal fibrosis in sheep23, 
and airway fibrosis in a mouse model of asthma24, as well as tissue fibrosis in other organs25,26. A selective KCa3.1 
blocker (senicapoc [ICA-17043]) administered orally was very well tolerated over 12 months in a human phase 
III clinical trial for sickle cell disease27,28.
In light of the above, we hypothesised that healthy lung parenchyma obtained from lung resection specimens 
stimulated with TGFβ1 ex-vivo, would recapitulate proximal TGFβ1-dependent pro-fibrotic events evident in IPF 
lungs, and that these would be inhibited by the selective KCa3.1 blocker senicapoc, but not dexamethasone. Part 
of this work has been presented previously in abstract form29,30.
Figure 1. Tissue viability after 7 days of ex vivo culture. (A) Representative H&E staining of tissue embedded 
on day 0 or after culture for 7 days in serum free medium, from the same donor. These images highlight 
that alveoli spacing (thin arrow), single cell alveoli walls (star), and vessel structures (thick arrow) remain 
intact after 7 days of ex vivo culture, with no visible signs of tissue necrosis. (B) Magnified images demonstrate 
preserved nuclear morphology with no sign of nuclear fragmentation. (C) Viability of the tissue was assessed 
using the MTS assay at day 0 and day 7. Tissue metabolic activity was similar at day 0 and day 7 in control tissue, 
and in the presence of TGFβ1 (10 ng/ml) or TGFβ1 ± 0.1% DMSO (n = 19). (D) Representative bioanalysis of 
RNA samples demonstrating crisp, clear 2:1 ratio’s of ribosomal RNA bands at 28 S to 18 S, and RIN values of all 
samples was >8.
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Figure 2. Differentially expressed genes in 7 day TGFβ1-stimulated lung tissue compared to control tissue.  
(A) Volcano plot identifying the statistically significant genes (p value) versus fold regulation (Log2(FC)) on the 
y and x axis respectively. Out of 84 genes, 41 were statistically significantly upregulated and 7 downregulated 
following a 5% false discovery analysis with John D. Storey adjusted p value < 0.05 and absolute value of 
log2(FC) ≥0.5, depicted by the dotted lines and grey shaded area (results are mean of 23 individual donors).  
(B) The log2 fold regulation of the 84 genes in individual donors is depicted in this heatmap, with mean 
log2(FC), and statistical significance indicated. Significance was calculated using a student’s t-test on the ∆∆CT 
for each gene. (C) Relative expression of ACT2A (αSMA mRNA) was significantly upregulated in TGFβ1-
stimulated tissue in comparison to control tissue, P = 0.0010, n = 11. (D) COL1A2 (collagen type 1 mRNA) 
expression was significantly increased in TGFβ1-stimulated tissue in comparison to control, P = 0.0058, 
n = 11. (E) Relative expression of COL3A1 (collagen type III mRNA) was significantly upregulated in TGFβ1-
stimulated tissue, P = 0.0296, n = 12. (F) SMAD2 mRNA expression was not significantly changed between 
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Results
Assessment of tissue viability and response to ex vivo culture. Lung tissue viability was assessed 
after 7 days of ex vivo culture by examining nuclear morphology, tissue necrosis, metabolic activity, and RNA 
quality, and compared to tissue at day 0. Nuclear morphology showed no signs of fragmentation and there were 
no visible signs of tissue necrosis (Fig. 1A and B). Alveolar structures were still identifiable. The MTS assay was 
used to determine the number of metabolically active cells present in tissue in media ± TGFβ1 (10 ng/ml) ± 0.1% 
DMSO at day 0 and day 7. Tissue metabolic activity was not significantly affected over the course of the 7 day 
culture, indicating that the number of viable cells was similar in all conditions (Fig. 1C). RNA isolated from days 
0 and 7 was assessed for quality, and 100% of the samples (n = 10 paired donors) were suitable for gene expres-
sion arrays. The total RNA isolated from the explanted tissue samples had an RNA integrity number [RIN] of >8 
(Fig. 1D).
We assessed differences in tissue fibroblast numbers and collagen staining between days 0 and 7 using immu-
nohisotchemistry. Collagens type I and III, and αSMA were quantified as % area stained, and FSP+ fibroblast-like 
cells counted (fibroblasts were distinguished from macrophages by morphology). No significant differences in 
collagen deposition, αSMA expression or fibroblast-like cell numbers were found (Supplementary Figure 1A–E). 
The presence of other cell types such as mast cells, macrophages were confirmed in both day 0 and day 7 cultures. 
Mast cell density assessed by immunohistochemistry for tryptase was 22.0 ± 4.7 cells/mm2 at day 0, and 24.8 ± 5.6 
cells/mm2 at day 7, p = 0.65.
Gene expression in tissue was compared between day 0 and day 7 tissue using the Qiagen RT2 profiling gene 
array (n = 9 donors). Of 84 genes examined, only 9 were significantly differentially expressed (5 upregulated, 4 
downregulated, Supplementary Table 1).
Therefore serum-free medium containing minimal essential nutrients is sufficient for the maintenance of 
viable, quiescent normal pulmonary parenchymal cells and architecture in ex-vivo lung tissue cultured for 7 days.
Modelling lung fibrogenesis in 7 day ex vivo culture. TGFβ1 has a pivotal and extensive role in the 
development of tissue fibrosis in IPF and other fibrotic disorders8,9,31,32. We therefore examined the tissue response 
to TGFβ1 (10 ng/ml) for 84 key genes implicated in human fibrotic processes, using the Qiagen RT2 PCR profiling 
array for human fibrosis. 41 pro-fibrotic genes were significantly upregulated in TGFβ1-stimulated tissue. All of 
these passed the false discovery rate (FDR) and 37 were upregulated with a log2-fold change (log2(FC)) of ≥0.5 
(≥0.5 is considered biologically significant)(Fig. 2A and B). 7 genes were significantly down regulated (Fig. 2A 
and B); all passed the FDR and 3 were downregulated with a log2(FC) of ≤−0.5. Notably, ECM collagens type 
I and III were upregulated, and numerous ECM remodelling enzymes, such as MMP3 which is a biomarker of 
IPF severity33 and predictor of shortened survival time34. mRNAs for many relevant cell adhesion molecules 
were upregulated including ITGB6 and ITGAV, subunits of the αvβ6 integrin. αvβ6 is an important component 
of TGFβ1 activation pathways in experimental animal models of fibrosis9,35, is increased in IPF patients36, and 
correlates with a worse prognosis36. Key pro-fibrotic cytokines and chemokines were also upregulated including 
CCL11 (eotaxin); CCL11−/− deficient mice have reduced bleomycin-induced pulmonary fibrosis and expres-
sion of pro-fibrotic cytokines such as TGFβ1 are diminished in the absence of CCL1137. Furthermore, several 
pro-fibrotic growth factors were upregulated, such as CTGF and PDGF, whose crosstalk with the TGFβ1 pathway 
are implicated in regulating fibrosis38–40. Interleukin-13 receptor alpha 2 (IL13RA2) was downregulated in this 
model of fibrogenesis which is notable as IL13RA2 is likely anti-fibrotic and plays a protective role in the lung by 
acting as a decoy receptor for IL-1341. Moreover, 16 of the 41 genes upregulated in this ex vivo model were upreg-
ulated in a previous study of IPF tissue, (Supplementary Table 2)34.
RT2 profiling gene array results were verified by individual qRT-PCRs21,22. The results were reproduci-
ble between methods and genes that were significantly increased using the RT2 profiling gene array (ACT2A, 
COL1A2, COL3A1), were increased to a similar extent using individual qRT-PCRs (Fig. 2C–E). Gene expression 
results were also consistent between techniques for genes that showed no significant change following 7 days of 
TGFβ1-sitmulation, SMAD2 and SMAD3(Fig. 2F,G). Log2(FC) were strongly correlated, correlation coefficient 
R2 = 0.8967 (Fig. 2H).
Immunohistochemistry was used to examine the tissue protein expression of selected upregulated genes and 
other pro-fibrotic markers. When we treated the tissue with TGFβ1 (10 ng/ml) for 7 days and compared this with 
control day 7 tissue, we observed significant increases in the expression of the ECM molecules collagens type I 
and III, αSMA and the numbers of FSP+ fibroblast-like cells present in the tissue (Fig. 3A–E). These findings are 
in keeping with other in vitro models of fibrosis21,42,43 and animal bleomycin models of fibrosis44,45.
Collagen secretion was also assessed in the supernatants collected after 4 days of ex vivo culture using the 
Sircol method, which utilises dye-binding for the analysis of newly synthesised ECM by quantifying acid and 
pepsin soluble collagens types I to V. After 4 days of ex vivo TGFβ1 exposure, collagen secretion into the super-
natants was significantly increased which is in accordance with the ECM genes that were upregulated (Fig. 3F).
Thus, this ex vivo model of human lung fibrogenesis recapitulates many molecular features identified in the 
lung tissue of individuals with IPF.
control or TGFβ1-stimulated tissue after 7 days ex vivo culture P = 0.4961, n = 9. (G) Similarly, relative 
expression of SMAD3 mRNA expression was also not changed following 7 days TGFβ1-stimulation, P = 0.4656, 
n = 8. (H) When comparing the log2 fold regulation of the 5 genes there was a strong correlation with the results 
found using Qiagen RT2 profiling gene array and qRT-PCR using different primers, R2 = 0.8967, P = 0.0392. 
Results are presented as mean ± SEM, ***P < 0.01, *P < 0.05.
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The selective KCa3.1 blocker Senicapoc (ICA-17043) attenuates TGFβ1-dependent fibrogenesis 
in human lung parenchyma. We predict that studying fibrogenesis in human tissue may prove effective 
for identifying drugs that have efficacy in IPF. KCa3.1 channels are a promising therapeutic target. Consistent 
Figure 3. Immunohistochemical analysis of TGFβ1-stimulated tissue compared to matched control tissue. (A) 
The percentage collagen type I staining in TGFβ1 (10 ng/ml)-stimulated tissue was significantly greater than in 
control tissue following 7 days of ex vivo culture, P = 0.0002, n = 13. (B) Similarly, collagen type III staining was 
increased in TGFβ1-stimulated tissue, as measured by percentage area stained, P = 0.0017, n = 13. (C) αSMA 
staining was significantly higher in TGFβ1-stimulated tissue, P = 0.0012, n = 13. (D) The number of fibroblast-
like cells assessed by counting cells stained with FSP antibody was increased following 7 days of TGFβ1-
stimulation in comparison to control tissue, P = 0.0006, n = 13. (E) Representative immunohistochemical 
staining is depicted for each antibody for both control and TGFβ1-stimulated tissue following 7 days of ex vivo 
culture, including representative images of relevant isotype controls. (F) Supernatants following 4 days of  
ex vivo culture were analysed for collagens type I to V using the Sircol dye base method. The amount of collagen 
secreted (µg/ml) was assessed per total weight of tissue present in the well (mg). Collagen was significantly 
increased in supernatants from TGFβ1-stimulated tissue in comparison to non-stimulated tissue following  
4 days of ex vivo culture, P < 0.0001, n = 15. Data are presented as median ± IQR, #P < 0.05, (Wilcoxon matched 
pairs signed rank test), or mean ± SEM **P < 0.01, ***P < 0.001 (paired t test).
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Figure 4. KCa3.1 modulation of TGFβ1-induced fibrotic gene expression in an ex vivo model of fibrogenesis. 
(A) Volcano plot demonstrating that out of 84 genes, 28 were significantly downregulated following treatment 
with Senicapoc for 7 days in comparison to TGFβ1-stimulation alone. A 5% false discovery analysis with John 
D. Storey adjusted p value < 0.05 and absolute value of log2(FC) greater than 0.5 was used, depicted by the dotted 
lines and grey shaded area (results are mean of 11 individual donors). (B) The individual fold regulation of 84 
genes is depicted in this heatmap, highlighting the magnitude of genes downregulated following treatment with 
senicapoc (100 nM) for 7 days. (C–E) Relative expression of ACT2A, COL3A1 and SMAD2 were significantly 
downregulated when treated with senicapoc, P = 0.0098, P = 0.0210, and P = 0.0078 respectively, consistent 
with RT2 profiling gene array results, n = 11. (F) No differences between TGFβ1 and TGFβ1+ 0.1% DMSO 
(vehicle control) were found using RT2 profiling gene arrays as displayed in the volcano plot identifying the gene 
expression of 84 fibrosis-associated genes. Results are presented as mean ± SEM, ***P < 0.01, *P < 0.05.
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with its ability to suppress pro-fibrotic activity in myofibroblasts, and structural changes within animal models 
of fibrosis, the selective KCa3.1 blocker senicapoc (100 nM [10x the Kd for channel block]) significantly attenu-
ated the TGFβ1-dependent upregulation of pivotal genes implicated in the development of IPF (n = 11 donors)
(Fig. 4A and B). Whereas 41 pro-fibrotic genes were upregulated by TGFβ1 compared to control, only 12 genes 
were upregulated by TGFβ1+ senicapoc compared to control (Supplementary Table 3).
When compared to TGFβ1+ 0.1% DMSO, 28 genes were significantly downregulated by senicapoc (Fig. 4A 
and B). These included ECM proteins (COL3A1) and myofibroblast markers (αSMA). Senicapoc also down reg-
ulated many cell adhesion molecules (ITGB6), pro-fibrotic growth factors (PDGFA), inflammatory cytokines 
and chemokine receptors (CCR2), matrix metallopeptidases (MMP2) and signal transduction and transcription 
factors (SMAD7, STAT1). These findings were supported by the use of selected RT-PCRs using custom primers 
for αSMA, collagen type III and SMAD2 (Fig. 4C–E). DMSO 0.1% did not have any effect when added to TGFβ1 
(Fig. 4F).
Immunohistochemical analysis supported the results from the profiling gene array, with reduced expression of 
collagens type I and III and αSMA, and a reduction in the number of FSP+ fibroblast-like cells within the tissue 
following 7 days of ex vivo culture with senicapoc compared to TGFβ1 alone (Fig. 5A–E). Staining was performed 
in paired sequential sections for FSP/αSMA, and collagen type 1/collagen type III, low power images of the same 
regions are depicted in Supplementary Figures 2 and 3.
Dexamethasone does not inhibit TGFβ1-dependent fibrogenesis. Corticosteroids are widely 
believed to be ineffective in IPF, and in combination with azathioprine increase mortality in IPF46. In contrast 
to the results for senicapoc, the corticosteroid dexamethasone (10 nM) had no overall effect on TGFβ1-induced 
fibrogenesis (n = 5)(Fig. 6A and B), likely due to its known failure to inhibit TGFβ activation pathways47. 
However, as expected, dexamethasone did inhibit mRNA for pro-inflammatory molecules such as inflammatory 
cytokines (IL-1α, IL-1β), similar to results from previous studies48,49. In summary, out of 84 genes examined 
in the presence of TGFβ1, dexamethasone downregulated 6 genes which passed the FDR, and upregulated 8 
pro-fibrotic genes at ≥0.5 log2(FC) which passed the FDR, including CTGF. These findings were supported by 
the use of selected RT-PCRs using custom primers for αSMA and collagens type I and III (Fig. 6C–E). Ethanol 
vehicle (0.1%) was without effect (Fig. 6F).
Effect of pharmacological intervention on collagen secretion. Collagen secretion was assessed in 
the supernatants collected after 4 days of ex vivo culture with TGFβ1 ± pharmacological intervention. Senicapoc 
was very effective at reducing the TGFβ1-dependent release of soluble collagen into the culture supernatants, 
whereas dexamethasone was ineffective (Fig. 7A and B).
Pharmacological intervention and key effector genes in TGFβ1-driven fibrogenesis. To further 
analyse the RT2 profiling data we determined the key genes driving the fibrotic response in the human tissue 
model. We used factor analysis to investigate whether there were distinct groups of genes (factors) regulating 
TGFβ1-induced fibrogenesis, using the TGFβ1-dependent gene expression results from 23 donors. Three factors 
were found that represented three sets of genes regulated by TGFβ1 (Table 1). These three factors were empha-
sised when examining the effects of pharmacological intervention. Senicapoc significantly inhibited 6 (out of 14) 
genes in factor 1 and 3 (out of 9) genes in factor 2 (Table 1). Furthermore, dexamethasone, which has no clinical 
efficacy in IPF, inhibited 1 (out of 14) genes in factor 1 but actually significantly upregulated 4 genes across fac-
tors 1 and 2. These results give some insight into how various pharmacological treatments mechanistically affect 
fibrotic processes in human lung tissue through inhibition of specific gene groups that can be determined by fac-
tor analysis. We hypothesise that a treatment which attenuates nearly all of the TGFβ1-dependent genes on each 
factor may be particularly effective for the treatment of IPF.
Discussion
TGFβ1 is a key growth factor driving tissue fibrosis in IPF9,10,32. We have demonstrated that ex vivo human lung 
parenchyma remains viable in tissue culture for at least 7 days, and in the presence of TGFβ1, upregulates many 
pro-fibrotic genes that are also upregulated in human IPF tissue34,36. This is accompanied by an increase in the 
number of tissue myofibroblasts and increased deposition of collagens type I and III demonstrated by immuno-
histochemistry. Importantly, these “fibrotic” TGFβ1-dependent changes were sensitive to pharmacological inter-
vention with a selective blocker of the pro-fibrotic KCa3.1 ion channel.
We believe this model has several advantages that will allow it to augment those currently used to study lung 
fibrosis. Firstly, by studying fibrotic events over 7 days, this reduces experimental time significantly over in vivo 
bleomycin studies. Secondly, the model avoids the relatively high financial costs and logistics of animal experi-
mentation. In contrast, this model uses excess tissue removed at surgery, and is relatively cheap. Thirdly, the use of 
human tissue removes the issue of cross-species heterogeneity which is difficult to account for when interpreting 
animal experiments designed to study human disease processes. Lastly, in contrast to the study of isolated cells or 
bioengineered tissues, the use of native human tissue explants maintains the complex 3D cell-cell and cell-matrix 
interactions present in human lung.
While this human lung model undoubtedly has limitations when considering the prolonged course of 
human IPF, it nevertheless provides a means to study the consequences of TGFβ1 exposure in the 3D lung tissue 
microenvironment. Many of the molecules upregulated in our limited fibrosis gene array are upregulated in IPF 
tissue, including those for matrix proteins, MMPs, integrins (ITGAV, ITGB6), αSMA, and growth factors (CTGF, 
PDGFα). Human IPF progresses over time, and TGFβ1 signalling is believed to be the central driver9,10,32. Thus 
drugs which are able to inhibit the downstream consequences of TGFβ1-dependent signalling have the potential 
to protect the remaining healthy lung and thus halt disease progression, although reversal of established fibrosis 
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is unlikely. This TGFβ1-dependent human lung model may therefore provide a reliable and rapid way of screen-
ing and identifying novel drugs for IPF treatment. Furthermore, the model provides the potential to study the 
downstream signalling networks activated by TGFβ1 in human parenchymal tissue, and how these are altered by 
drug exposure.
In human IPF tissue, FSP+ cells are predominantly fibroblasts50, although FSP is also expressed by tissue mac-
rophages. For our analysis we only counted cells with a fibroblast-like morphology. It is also reported that murine 
endothelial cells and vascular smooth muscle cells express FSP51 but this was not evident in our human lung 
Figure 5. Senicapoc inhibits TGFβ1-induced pro-fibrotic structural responses in the 7 day ex vivo tissue model. 
(A) Analysis of production of collagen type I, collagen type III, αSMA, and fibroblast cell numbers following 
exposure to TGFβ1 with or without the KCa3.1 inhibitor senicapoc (100 nM). 0.1% DMSO was used as vehicle 
control. Senicapoc significantly attenuated TGFβ1-dependent pro-fibrotic responses within the tissue over 
7 days ex vivo culture, n = 10 individual donors. Data are presented as median ± IQR, ##P < 0.01 (Wilcoxon 
matched pairs signed rank test), or mean ± SEM **P < 0.01, ***P < 0.001 (paired t test). (B) Representative 
immunohistochemical images of 7 day ex vivo culture tissue under various conditions, un-stimulated control, 
TGFβ1-stimulated plus 0.1% DMSO and TGFβ1-stimulated treated with senicapoc (100 nM). Control and 
treated tissues were matched.
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Figure 6. The effects dexamethasone on TGFβ1-induced fibrotic gene expression. (A) Volcano plot displaying 
the 11 differentially expressed genes following treatment with dexamethasone for 7 days in comparison 
to TGFβ1 alone, n = 5 donors. Treatment with dexamethasone resulted in the upregulation of 6 genes and 
downregulation of 8 genes passing 5% false discovery analysis with John D. Storey adjusted p value < 0.05 and 
absolute value of Log2(FC) greater than 0.5, depicted by the dotted lines and grey shaded area (results are mean 
of 5 individual donors). (B–D) Relative expression of ACT2A, COL1A1 and COL3A1 were unchanged when 
the TGFβ1-stimulated tissue was cultured with dexamethasone (10 nM) (F) Similarly, 0.1% ethanol (vehicle 
control for dexamethasone) did not affect TGFβ1-stimulated fibrogenesis highlighted in the volcano plot 
identifying the gene expression of 84 fibrotic genes.
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explants. The increase in the number of fibroblast-like cells expressing FSP in our study following TGFβ1 stimula-
tion of lung tissue is therefore consistent with previous observations from IPF tissue, while the ability of senicapoc 
to inhibit this is consistent with its ability to inhibit the proliferation and differentiation of primary human lung 
myofibroblasts20.
Figure 7. Pharmacological intervention in the fibrogenesis model has varying effects on collagen secretion 
after 4 days ex vivo culture. (A) KCa3.1 blockade significantly attenuated collagen secretion into the supernatants 
following 4 days of ex vivo culture. The amount of collagen secretion was examined per mg of tissue present 
in the well, n = 5. (B) Dexamethasone (10 nM) did not inhibit TGFβ1-stimulated collagen secretion into the 
supernatants following 4 days of ex vivo culture n = 5. Data are presented as median ± IQR #P < 0.05 (one 
sample t test), or mean ± SEM *P < 0.05, (1-way ANOVA, corrected by Dunns multiple comparison test).
Genes Factor 1 Factor 2 Factor 3 Senicapoc Dexamethasone
TGFBR1 0.977 ↓
SMAD4 0.968 ↓ ↑
SMAD7 0.913 ↓
TIMP2 0.876
PLAU 0.876 ↓
SNAI1 0.865
TGFBR2 0.840 ↑
ITGB1 0.813
ITGA1 0.766 ↓
THBS1 0.758
TIMP1 0.745
ITGB3 0.724 ↓
THBS2 0.722
CXCR4 0.712 ↓
LOX 0.748 ↑
ACTA2 0.885 ↓
CAV1 0.944 ↓ ↑
COL1A2 0.979
CTGF 0.915
ENG 0.866 ↓
CCL2 0.848
ITGB5 0.927
CCL11 0.782
TIMP3 0.874
TIMP4 0.911
SERPINE1 0.780
Table 1. Factor analysis of TGFβ1-dependent fibrogenesis.
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In this study we have used immunohistochemistry and measurement of soluble collagen to validate selected 
gene expression changes identified by PCR array. We believe immunohistochemistry has advantages over 
other methods such as western blotting in that it is readily quantifiable using cell counts and image analysis, 
the analysis is highly reproducible, it allows analysis of tissue areas of interest, and subtle changes within tis-
sue sub-compartments can be identified52–55. In contrast, western blotting of whole tissue extracts while 
semi-quantifiable, is open to marked confounding by the variable tissue components that might be present from 
sample to sample. For example, if one sample contains a large blood vessel, the αSMA actin will be greatly skewed. 
Using immunohistochemistry, such vessels can be readily excluded if not relevant to the analysis.
For this human lung model to be useful in drug development for IPF, it needs to be responsive to pharmaco-
logical intervention. Pirfenidone has been approved recently for use in IPF. It has modest efficacy, and attenuates 
the decline in lung function, although it’s mechanism of action is poorly understood. Nintedanib is also approved 
for IPF, with similar efficacy to pirfenidone. Currently these two drugs are the clinical benchmark with which to 
test potentially novel therapies in model systems. However the pathways and mechanisms involved in pirfenidone 
treatment are understudied and it is unclear how it is exerting its affects. This model therefore has the potential 
to improve understanding of the mechanism of action of pirfenidone in future studies, which in turn may lead to 
the development of improved medicines working through a similar mechanisms of action.
The KCa3.1 ion channel promotes TGFβ1-dependent activation through the regulation of SMAD2/3 nuclear 
translocation and downstream transcription20–22. As a result, blocking or silencing KCa3.1 inhibits the pro-fibrotic 
activity of parenchymal human lung myofibroblasts, and prevents tissue fibrosis in several animal models25,26, 
including bleomycin-dependent fibrosis in sheep23. In our current model, KCa3.1 blockade using senicapoc, a 
drug very well tolerated in a phase 3 clinical trial of human sickle cell disease, was highly effective at inhibiting the 
pro-fibrotic effects of TGFβ1 both in terms of gene transcription, and tissue protein markers of fibrosis. Indeed, 
many genes known to be upregulated in IPF tissue were downregulated by senicapoc. Thus the current in vitro 
human evidence, the mouse and sheep in vivo data, and the favourable safety profile in human subjects suggest 
that clinical trials of KCa3.1 blockade in IPF should be considered seriously.
In contrast to the effects of senicapoc, the corticosteroid dexamethasone was ineffective at inhibiting the 
effects of the pro-fibrotic features of TGFβ1 in this model, and upregulated some pro-fibrotic mediators. While 
corticosteroids alone have not been adequately assessed in randomised controlled clinical trials, there is evidence 
to suggest that they are ineffective in IPF56,57, and they increase mortality in combination with azathioprine46. 
There is therefore concordance between the inefficacy of corticosteroids in our model and their inefficacy in 
human IPF.
Alsafadi et al. recently published a model of human lung fibrogenesis similar to ours although they used pre-
cision cut lung slices on human lung inflated with agarose, and used a cocktail of TGFβ1, TNFα, PDGF-AB, and 
lysophosphatidic acid to activate pro-fibrotic pathways58. They demonstrated that their PCLS remained viable for 
at least 5 days assessed by tissue morphology and metabolic activity. Using qRT-PCRs for a few selected genes 
they demonstrated the upregulation of FN1, SERPINE1, COL1A1, CTGF, MMP7, and ACTA2, supported by west-
ern blotting and immunohistochemistry for the respective proteins (n = 4–6 donors), and the measurement of 
soluble collagen in the supernatants. Their results are therefore broadly in keeping with ours although the analysis 
was more limited in terms of genes of interest and donor numbers. We have shown that the pro-fibrotic response 
to TGFβ1 is consistent across a large number of donors although some donor-specific heterogeneity is inevitably 
present, and demonstrate that the model is sensitive to pharmacological intervention. Furthermore, Alsafadi 
et al. acknowledged a key limitation of their study was the lack of significant αSMA induction due to short cul-
ture times of PCLS. In our model 7 days culture was sufficient to see ECM remodelling and induce pathological 
αSMA changes. We believe that the major advantage of our model is the simplicity, with avoidance of inflation 
with agarose. Lung inflation with agarose requires access to intact lobes, but these are often not intact once the 
area affected by tumour has been removed for pathological assessment. In contrast, our model can be applied to 
distal lung parenchyma unsuitable for inflation.
A recent study used tissue derived from IPF patients to examine the activity of a PI3K/mammalian target of 
rapamycin (mTOR) inhibitor and showed that this inhibited Akt phosphorylation59. Studying IPF tissue is clearly 
useful, but relatively difficult to obtain for ex vivo studies as its collection relies on the availability of “end-stage” 
lungs removed for transplantation. In contrast, the use of healthy areas of lung from surgery, predominantly for 
carcinoma, is relatively straightforward, with over 250 surgical lung procedures in our hospital alone per annum.
In summary, we believe our ex vivo model of human lung fibrogenesis has the potential to simplify and accel-
erate the evaluation of potential therapeutic targets and associated therapies for human lung fibrosis, while at the 
same time providing insight into the mechanism of drug action. Thus, this model may represent an invaluable 
new tool to facilitate the analysis of TGFβ1-driven fibrogenic mechanisms and advance pre-clinical biomarker 
and drug discovery for IPF. Lastly, this study further strengthens the case for undertaking clinical trials of the 
KCa3.1 blocker senicapoc in IPF.
Methods
Tissue collection. Human lung tissue samples (n = 40) were obtained from healthy areas of lung from 
patients undergoing lung resection for carcinoma at Glenfield Hospital, UK. All patients gave written informed 
consent and the study was approved by the National Research Ethics service (references 10/H0402/12 and 07/
MRE08/42). All methods were performed in accordance with the relevant guidelines and regulations. Samples 
obtained were anonymised and coded before use. Patient demographics are shown in Table 2.
Tissue Explant Culture model. Healthy areas of tissue from lung resection surgery were cut into approxi-
mately 2 mm3 pieces and 4 pieces of tissue per well were placed into 6 well plates. Once cut, tissue was submerged 
in 3 ml of Dulbecco’s modified eagles medium (DMEM) supplemented with antibiotic/antimycotic agents and 
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non-essential amino acids. Explanted tissue was cultured for 7 days in various conditions; serum-free medium 
alone, or serum-free medium plus: TGFβ1 (10 ng/ml), 0.1% DMSO, TGFβ1 (10 ng/ml) + 0.1% DMSO, TGFβ1 
(10 ng/ml) + senicapoc (100 nM), TGFβ1 + 0.1% ethanol, TGFβ1 + dexamethasone (10 nM). Separate plates and 
tissue were used for RNA experiments and immunohistochemistry experiments. On day 4, supernatants were 
collected and culture media refreshed. On day 7 tissue was harvested.
RNA Extraction. Tissue was placed into RNA later and stored at either +4 °C for 1 week or −20 °C for up 
to 1 month before isolation. Tissue was then placed in 300 µl of Qiagen buffer RLT with β-mercaptoethanol and 
homogenised using Precellys® hard tissue homogenizing tubes in the Precellys® 24 tissue homogenizer (Bertin 
Technologies, Montigny-le-Bretonneux, France) under a protocol adapted for lung tissue samples; 2 cycles at 
6400 rpm for 30 seconds. Total RNA was purified using the automated QIAcube with RNeasy Fibrosis Mini kit 
(Qiagen, CA, USA) according to the manufacturer’s instructions. The RNA concentration and quality was meas-
ured using the Bioanalyzer 2100 system (Agilent, CA, USA). All samples, including day 0 and day 7 samples 
presented high-quality RNA with RNA integrity numbers of >8. RNA concentrations were then measured using 
the Nanodrop 2000 (Labtech International, East Sussex, UK).
RT2 Profiling PCR Fibrosis Array. cDNA was pre-amplified using the RT2 first strand cDNA kit, according 
to manufacturer’s instructions (SabBioscience, Qiagen). A RT2 profiler human fibrosis PCR array (PAHS-120ZA) 
was performed for quantitative PCR in the Strategene MX3000P system according to the manufacturer’s instruc-
tions. Each PCR array plate examines 84 genes and has performance and quality controls for reverse transcrip-
tion, genomic DNA contamination and PCR reproducibility. Any plate that did not pass was re-run; all the plates 
included in this paper passed. Ct was defined as 41 for the ΔCt calculation when the signal was below detectable 
limits. The average CT values of beta-2-microglobulin (β2M) and beta actin (β-actin) housekeeping genes were 
used as normalising controls. Results were calculated using the 2−ΔΔCt method60. A minimum and maximum log 
2 fold change of +5 to −5 was applied.
Real time PCR analysis. Quantitative Real-time PCR (qRT-PCR) was used to measure mRNA expression 
levels of αSMA (ACT2A), collagen type I (COL1A1), collagen type III (COL3A1), SMAD2 and SMAD3, as a 
validation of the array data. All primers were validated (primer efficiency confirmed to be between 90–105%), 
sequenced and have previously been published21,22,61. PCR products were run on a 1.5% agarose gel to confirm 
product size and each product was sequenced to confirm specificity of the primers. Gene expression was quan-
tified using Brilliant SYBR Green QRT-PCR 1-Step master mix (Strategene, the Netherlands) in the Strategene 
Characteristic n = 40
Sex
  Male 18 (45)
  Female 22 (55)
Age (yrs)
  Mean (±SEM) 65 ± 1.83
  Range 31–82
Smoking history
  Never 5 (12.5)
  Ex <12 months pre-operatively 6 (15)
  Ex >12 months pre-operatively 17 (42.5)
  Current 7 (17.5)
  Unknown 5 (12.5)
Number of Pack Years
  Mean (±SEM)) 39.3 ± 3
  Range 0–70
Lung Function
  FEV1 1.826 ± 0.1242
  FEV1 (% predicted) 72.3 ± 4.29
  FVC 2.98 ± 0.1396
  FVC (% predicted) 96.87 ± 3.92
  FEV1/FVC ratio (%) 61.16 ± 3.172
Diagnosis
  Non small cell 33 (82.5)
  Carcinoid 5 (12.5)
  Combined neuroendocrine carcinoma 1 (2.5)
  Lung volume reduction surgery 1 (2.5)
Table 2. Demographics of tissue donors. Note: data presented as n (%) or mean ± SEM. Abbreviations: FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity.
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MX3000p system. All expression data were normalized to β-actin using Quantitect primer assay primers (Qiagen, 
Germany), HS_ACTB_1_SG and corrected using the reference dye ROX. For each experiment >50% of the sam-
ples used were also used for the RT2 profiler human fibrosis PCR array.
GMA embedding and immunohistochemistry. Tissue was fixed in ice-cold acetone containing 
2 mM phenylmethylsulfonyl fluoride and 20 mM iodoacetamide overnight at −20 °C and embedded in GMA, 
cut and stained as previously described62, two sections at least 10 μM apart were stained for each antibody. 
Haematoxylin and eosin (H&E) staining was used to determine tissue morphology. Primary antibodies were 
used against the following antigens: anti-alpha smooth muscle actin (αSMA), clone 1A4 (0.7 µg/ml;, Dako UK, 
Ely, United Kingdom); anti-fibroblast surface protein (FSP), clone 1B10 (4 µg/ml; Sigma-Aldrich, Dorset, UK); 
anti-collagen type I (550346, 15 μg/ml, Millipore, Watford, UK); anti-collagen type III, clone FH-7A (3.125 µg/
ml; Sigma-Aldrich, Dorset, UK); and appropriate isotype controls mouse IgG1, and mouse IgG2a (Dako). The 
sections were incubated with appropriate secondary antibody polyclonal rabbit anti mouse F(ab)2 biotinylated 
(2.5 µg/ml, Dako), incubated with streptavidin-biotin peroxidise complex detection system (Dako, UK) for 2 h, 
treated with chromogen aminoethylcarbazole (AEC) giving a red reaction product, and counterstained with 
Mayer’s haematoxylin.
Image analysis and quantitative morphometry. Measurement of αSMA immunostaining area. 
Immunoreactivity for αSMA was measured by a single observer at ×200 magnification using and was expressed 
as the percentage area of lung parenchymal tissue stained. To allow for biopsy variation, for each condition 2 sep-
arate blocks were immunostained and analysed. The mean measurement from 2 sections per block, at least 10 µM 
apart was used to determine the final value.
Measurement of extracellular matrix deposition. For quantitative assessment of matrix deposition in the lung 
parenchyma, a thresholding technique previously developed on the basis of hue, saturation and intensity (HSI) 
was used as described63. Areas of immunostained collagen type I and type III were assessed by a single observer 
at ×200 magnification, in 2 sections at least 10 µM apart and expressed as percentage area of lung parenchymal 
tissue stained.
Determination of fibroblast numbers. Nucleated immunostained cells for FSP-1 (fibroblast-like cells and 
myofibroblast-like cells) were counted in the explant tissue at ×400 magnification and expressed per mm2 of lung 
parenchymal tissue. Macrophages stained with this antibody were excluded from cell counts and analysis. The 
mean cell count of 2 sections at least 10 µm apart was used to determine the final count. Counts were enumerated 
by 2 blinded observers with excellent agreement, reliability and repeatability (Cronbach’s Alpha intra-class cor-
relation coefficient 0.906).
Collagen Secretion. Soluble collagen in the supernatants after 4 days of tissue culture was quantified using 
the Sircol collagen assay (Biocolor, County Antrim, UK) according to manufacturer’s instructions.
MTS Assay. Human lung tissue viability was assessed by the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carb
oxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay (Promega, Wisconsin, USA), as per manufacturer’s 
instructions. At day 0, and day 7, tissue was removed from culture, placed into a 96 well plate along with 150 µl 
of serum free media and 30 µl MTS reagent. Plates were incubated for 2 hours at 37 °C and then each piece of 
tissue was removed from the well and weighed. The plate was then placed in the Enspire Multimode plate reader 
(PerkinElmer, Massachusetts, USA) at 490 nM for 0.1 second. The viability of the tissue was assessed using the 
equation below to determine the Viability Index number (equation 1). Experiments were performed in duplicate.
=Viability Index Absorbance (490 nM)
Tissue weight (g) (1)
Statistics. The RT2 profiling gene array has in-built reproducibility controls and therefore only one plate 
per donor was run. Other experiments from an individual donor were performed in duplicate or triplicate and 
a mean value was derived for each condition. Data distribution across donors was tested for normality using the 
Kolmogorov-Smirnov test. For parametric data, the one-way ANOVA or repeated measures ANOVA for across 
group comparisons was used followed by the appropriate multiple comparison post hoc test; A paired t test was 
used for groups of only two conditions on the same donor. For non-parametric data, the Friedman test was 
used for across group comparison of paired data followed by the appropriate multiple comparison post hoc test; 
otherwise a Wilcoxon rank sum test was used. Graph Pad Prism (version 6, GraphPad Software, San Diego, CA, 
USA) was used for these analyses. A value of P < 0.05 was taken to assume statistical significance and data are 
represented as mean (±SEM) or median (±IQR).
False discovery analysis was performed on all RT2 PCR profiling array data to overcome the problems of 
multiple testing. This was undertaken using John D. Storey adjusted p-value < 0.05 and q-value of 0.05 (5% FDR) 
derived from the full list of p-values.
Factor Analysis. Factor analysis was carried out in SPSS on the fold change data of the TGFβ1 derived 
expression. The Factor analysis was carried out to determine if patterns of expression could be found within 
the correlated gene expression and thus see if different groups of genes behaved differently within tissue when 
TGFβ1 was applied. Due to the large number of genes recorded compared to the number of donor, the principle 
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component analysis method was used to determine the number of factors and their factor loading within the 
correlated expression. The number of factors was chosen based on the Kaiser criterion of factors having eigen 
values of greater than one and then keeping the factors that had a least one factor loading greater than 0.7 as factor 
loading below this are difficult to interpret.
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